From MDT to MTB: the paradigm revolution in pediatric cancer treatment in the era of precision medicine
Open Access
- 4 July 2025
- journal article
- review article
- Published by Springer Nature in Holistic Integrative Oncology
- Vol. 4 (1) , 1-5
Abstract
Pediatric cancer treatment is undergoing a paradigm shift from multidisciplinary team (MDT) approaches to molecular tumor boards (MTB). This article analyzes the limitations of traditional MDT, the technological reconstruction path of MTB, and the dual challenges of ethics and resource allocation in precision medicine. It reveals the fundamental transformation of the diagnostic and treatment system driven by genomics and proposes integrated strategies for future development.Keywords
This publication has 15 references indexed in Scilit:
- Accelerating the understanding of cancer biology through the lens of genomicsCell, 2023
- A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular EraCancer Discovery, 2021
- The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence TargetsCancer Discovery, 2021
- Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancerNature Medicine, 2020
- Genotypes versus phenotypes: The potential paradigm shift in the diagnosis and management of pediatric neoplasmsPediatric Investigation, 2020
- Molecular characteristics and therapeutic vulnerabilities across paediatric solid tumoursNature Reviews Cancer, 2019
- Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT studyNature Medicine, 2019
- The landscape of genomic alterations across childhood cancersNature, 2018
- International incidence of childhood cancer, 2001–10: a population-based registry studyThe Lancet Oncology, 2017
- Chemotherapeutic approaches for newly diagnosed hepatoblastoma: Past, present, and future strategiesPediatric Blood & Cancer, 2012